Latest advances in treatments for psoriatic arthritis: Newly developed medications
Latest Developments in Psoriatic Arthritis Treatments
In the ever-evolving landscape of medical advancements, new and emerging treatments are making a significant impact on the management of Psoriatic Arthritis (PsA). Here's a round-up of the latest approved and promising treatments for PsA.
Approved Treatments:
- TREMFYA® (guselkumab): This groundbreaking treatment is the first and only fully-human, dual-acting monoclonal antibody to receive approval for PsA. TREMFYA blocks IL-23 and also binds to CD64, a receptor on cells producing IL-23. Clinical data from the APEX study demonstrated a consistent safety profile and effective inhibition of joint damage, with efficacy measured by ACR20 responses (20% improvement in tender/swollen joints and other clinical criteria) [1].
- Ilumya® (tildrakizumab): Recently approved for PsA treatment, Ilumya demonstrated positive phase 3 results in two global, randomized, placebo-controlled trials (INSPIRE-1 and INSPIRE-2), involving over 800 patients with active PsA. Tildrakizumab significantly improved PsA symptoms at 24 weeks compared to placebo, both in biologic-naïve and biologic-experienced patients. It is usually administered every 12 weeks and allows concomitant use of methotrexate or leflunomide [2][3].
Emerging Treatments:
- Zasocitinib (TAK-279): This investigational oral TYK2 inhibitor has shown promising results in a phase 2b trial. After 12 weeks, it significantly improved both joint and skin symptoms in patients with active PsA. Zasocitinib's selectivity may offer safety advantages over broader JAK inhibitors, which have been associated with serious side effects like cancer and cardiovascular events [4].
In summary, TREMFYA and Ilumya are newly approved agents with strong clinical trial evidence supporting their efficacy and safety in managing PsA, including inhibition of joint damage and symptom relief. Zasocitinib represents a promising oral treatment option in development that could provide effective and potentially safer therapy by selective TYK2 inhibition.
Key Clinical Trial Outcomes:
| Treatment | Mechanism | Trial Phase & Design | Efficacy Measure | Notes | |-----------------|---------------------------------|-------------------------------------|--------------------------------------------|--------------------------------------------| | TREMFYA | IL-23 inhibitor + CD64 binding | Phase 3 (APEX) | Significant inhibition of joint damage; ACR20 response | First IL-23 inhibitor approved to inhibit joint damage in PsA | | Tildrakizumab | IL-23 inhibitor | Phase 3 (INSPIRE-1 & -2) | Significant symptom improvement at 24 weeks; ACR20 | Efficacious in biologic-naïve and experienced patients | | Zasocitinib | Oral selective TYK2 inhibitor | Phase 2b | Significant improvement in joint and skin symptoms at 12 weeks | Potential enhanced selectivity and safety vs. JAK inhibitors |
This information reflects the most recent published clinical trial data and regulatory approvals as of mid-2025 [1][2][3][4].
- Deucravacitinib, a tyrosine kinase 2 inhibitor, is effective and well-tolerated, according to phase II clinical trials. Phase 3 studies are currently ongoing.
- Guselkumab (Tremfya) is a new interleukin blocker that has FDA approval for the treatment of PsA.
- Bimekizumab, a monoclonal antibody that blocks IL-17A and IL-17F, has shown promising results as a safe and effective treatment for PsA in phase 1 and 2 studies.
- Weight management may play a key role in managing and treating PsA, as people with obesity had a higher risk of not responding to biologic medications than those without obesity, according to a 2018 systematic review.
- Approximately one-third of people with psoriasis develop psoriatic arthritis (PsA).
- Risankizumab-rzaa is the second IL-23 inhibitor that has FDA approval for the treating active PsA in adults.
- Upadacitinib (Rinvoq) is another JAK inhibitor that has approval for treating PsA.
- Rheumatologists and dermatologists are typically those who treat PsA.
- Brodalumab, which binds to IL-17RA, may be more effective in treating moderate-to-severe cases of PsA than other biological therapies, according to some research.
- Newly approved treatments for Psoriatic Arthritis (PsA) include TREMFYA® (guselkumab) and Ilumya® (tildrakizumab), both demonstrating strong clinical evidence for their efficacy and safety.
- The investigational oral TYK2 inhibitor Zasocitinib (TAK-279) has shown promise, improving both joint and skin symptoms in patients with active PsA in a phase 2b trial.
- Deucravacitinib, another tyrosine kinase 2 inhibitor, has been found effective and well-tolerated in phase II clinical trials, with phase 3 studies currently ongoing.
- Bimekizumab, a monoclonal antibody that blocks IL-17A and IL-17F, has shown potential as a safe and effective treatment for PsA in phase 1 and 2 studies.
- Weight management could play a significant role in managing and treating PsA, as people with obesity may have a higher risk of not responding to biologic medications.
- Psoriatic arthritis (PsA) affects approximately one-third of people with psoriasis, making it a common chronic disease for psoriasis seekers and switchers to be diagnosed with.
- In addition to TREMFYA, Risankizumab-rzaa, Upadacitinib (Rinvoq), and Brodalumab are other treatments that have received FDA approval for the management of PsA, catering to various health-and-wellness needs and skin-care concerns related to neurological-disorders and skin-conditions.
